Scientific Liaison Coalition (SLC) Annual Report
January 2014
(Updated November 2014)

Current Participating SLC Organizations

American Association for Cancer Research (AACR)
American Academy of Clinical Toxicology (AACT)
American College of Medical Toxicology (ACMT)
American College of Toxicology (ACT)
The Endocrine Society (ENDO)
Environmental Mutagenesis and Genomics Society (EMGS)
International Society for the Study of Xenobiotics (ISSX)
Safety Pharmacology Society (SPS)
Society for Risk Analysis (SRA)
Society of Environmental Toxicology and Chemistry (SETAC)
Society of Toxicologic Pathology (STP)
Society of Toxicology (SOT)
Teratology Society (Teratology)

Current SLC Governance Committee (SLCGC)

Mary Jeanne Kallman (SPS), Chair
Florence G. Burleson (ACT), Incoming Chair
Kevin S. McDorman (STP), Immediate Past Chair
Rosalie K. Elespuru (EMGS), Coalition Society Representative
Peter L. Goering (SOT Council Contact), Society Representative
Kenneth L. Hastings (SOT), Coalition Society Representative
Thomas B. Knudsen (Teratology), Coalition Society Representative, at–large
Kenneth E. McMartin (AACT), Coalition Society Representative
Donna L. Mendrick (SOT), Coalition Society Representative at–large
Marcia G Lawson (AIM, Inc.), SLC Administrator
Current SLC Representatives

AACR: Thomas W. Kensler
AACT: Kenneth E. McMartin
ACMT: Stephen Munday
         Suzanne R. White
ACT: Florence Burleson
ASPET: John D. Schuetz
ENDO: Loretta L. Doan
EMGS: Rosalie K. Elespuru
ISSX: Steven C. Kemp
SPS: Mary Jeanne Kallman
SETAC: Patrick D. Guiney
SRA: John R. Fowle, III
STP: Daniela Ennulat
         Jack R. Harkema
         James E. Klaunig
SOT: Kenneth L. Hastings
         Thomas B. Knudsen
         Paul B. Watkins
Teratology: John M. DeSesso
             Elaine Z. Francis
             Edward S. Hunter
             Mary Alice Smith
### 2014 Accomplishment:

The FutureTox II: *In Vitro* Data and *In Silico* Models for Predictive Toxicology

Contemporary Concepts in Toxicology (CCT) conference drew 291 presenters, attendees, and exhibitors from around the globe (e.g., Europe, Asia, and South American) on January 16–17, 2014, at the William and Ida Friday Center for Continuing Education, University of North Carolina, Chapel Hill, North Carolina. In addition, nine sites participated in a webcasting pilot program to expand the reach of these CCT meetings. The conference addressed the pathway-based strategy by bringing together basic research into a congress that integrated newer *in vitro* methodologies and computational (*in silico*) modeling approaches with advances in systems biology.

As SOT 2013–2014 President Lois D. Lehman–McKeeman noted in her Welcoming Statement: "The FutureTox II Organizing Committee has worked diligently to develop this international forum that brings together distinguished experts and attendees from academia, industry, and government to discuss the integration of newer *in vitro* methodologies and computational modeling approaches with advances in systems biology. The overarching goal of this conference is to address the strengths and weaknesses of these novel approaches and to clarify the usefulness and validity of these new technologies. Such critical discussion will also help to ascertain their overall utility in both the regulatory and regulated scientific communities."

The FutureTox II CCT Organizing Committee developed the scientific program for this meeting and included the following members: Thomas B. Knudsen, Co-Chair, US Environmental Protection Agency (US EPA), Research Triangle Park, North Carolina; Douglas A. Keller, Co-Chair, Sanofi US, Bridgewater, New Jersey; Edward W. Carney, Dow Chemical Company, Midland, Michigan; Nancy G. Doerrer, ILSI Health and Environmental Sciences Institute, Washington, DC; David L. Eaton, University of Washington, Seattle, Washington; Suzanne Compton Fitzpatrick, US Food and Drug Administration (US FDA), Silver Spring, Maryland; Kenneth L. Hastings, Sanofi US, Bethesda, Maryland; Donna L. Mendrick, US FDA/National Center for Toxicological Research, Silver Spring, Maryland; Raymond R. Tice, National Institute of Environmental Health Sciences/National Toxicology Program, Research Triangle Park, North Carolina; Paul B. Watkins, University of North Carolina, Chapel Hill, North Carolina, and The Hamner Institutes for Health Sciences, Research Triangle Park, North Carolina; Maurice Whelan, European Commission, Joint Research Centre, Ispra, Italy; and Ivan Rusyn, SOT Council Contact, University of North Carolina, Chapel Hill, North Carolina.
While some aspects of this topic were covered in the October 2012 FutureTox CCT meeting, FutureTox II CCT provided a forum for a detailed scientific discussion of how the biological pathways of interest will be elucidated, characterized, and qualified for pathway-based risk assessment. The Society of Toxicology appreciates the generous contributions of the following FutureTox II sponsors: American Academy of Clinical Toxicology, American Chemistry Council, American College of Toxicology, Consumer Specialty Products Association, Elsevier, Grocery Manufacturers Association, The Hamner Institutes for Health Sciences, ILSI Health and Environmental Sciences Institute, Office of Environmental Health Hazard Assessment (OEHHA)/California Environmental Protection Agency (Cal/EPA), Teratology Society, Society of Toxicologic Pathology, Department of Environmental Sciences and Engineering, Gillings School of Public Health, University of North Carolina, Chapel Hill; US EPA, and US FDA. A Forum Report of this conference will be submitted for publication in *Toxicological Sciences*.


**Planning Underway**: FutureTox III: Transforming 21st Century Science into Risk Assessment and Regulatory Decision–Making, November 19–20, 2015, Crystal City, Virginia

**2012–2013 Accomplishments**

1) American College of Toxicology Joins the Scientific Liaison Coalition.

2) Alerts provided as to the air transportation of research animals and the impact of federal government sequester on scientific meeting attendance. This resulted in several organizations joining each effort.

3) Fact Sheet developed titled “Communicating Biomedical Health–Related Research Findings: A Guide to Maintaining Balance and Avoiding Common Pitfalls” that will be distributed to sponsoring organizations.

4) SOT FutureTox II Contemporary Concepts in Toxicology (CCT) Conference, Pathways to Prediction: *In Vitro* Data and *In Silico* Models for Predictive Toxicology, to be held January 16-17, 2014, Chapel Hill, North Carolina. Members from all SLC participating organizations receive the SOT member rate for early registration.

5) SLC-Sponsored session proposal on “Biomarkers of Disease and Toxicity: Exploiting the Interconnections” (Donna Mendrick) accepted as a Symposium for the 2013 SOT Annual Meeting. This session was one chosen to be recorded and is now posted on the SOT website.
6) SLC-endorsed session proposal on “Life Course Factors and Models for Children’s Health Risk Assessment” (Sally Darney) accepted as a Workshop Session for the 2013 SOT Annual Meeting. In addition, this is one of four 2013 SOT Annual Meeting sessions that will be presented at the 2014 AAAS Annual Meeting, February 13–17, 2014, Chicago, Illinois.

7) SLC-Sponsored session on “Understanding Toxic Neuropathy Related to Oncology Drugs: Both Clinical and Non-Clinical Perspectives” (John Benitez, former AAMT representative and Mary Jeanne Kallman) accepted as CE course for 2013 SOT Annual Meeting. Dr. Kallman is in the process of encouraging other societies to consider inclusion of this session at their Annual Meetings.

8) SLC-Sponsored session proposal on “Adverse Outcome Pathways (AOPs) in Predictive Toxicology” (Tom Knudsen) accepted as symposium for the 2013 Teratology Meeting.

9) SLC-Sponsored session proposal “Elucidating Adverse Outcome Pathways (AOPs) for Developmental Toxicity” accepted as a Continuing Education Course for 2014 SOT Annual Meeting.

10) SLC-endorsed session on “Translation of Tox21 Data for Human Health Risk Assessment” (Rosalie Elespuru and Tom Knudsen) will be presented at the STP 2014 Annual Symposium in Washington, DC, June 2014.

Progress on Long-Term Strategic Objectives
As noted above, there has been significant progress aligned with the stated mission of the SLC as provided below.

Mission: Improving the ability of societies to partner with other domestic and international organizations that have objectives consistent with the goal of increasing the impact of the science of toxicology to improve public health

- Strengthening partnerships among scientific and health-based organizations to increase awareness of the impact of toxicology and related subjects on human health
- Functioning as a means to enhance cooperation among societies as equals with the goal of accomplishing tasks benefiting human health and disease prevention through joint and several shared activities